Total Payments
$2,594
2024 Payments
$566.41
Companies
39
Transactions
129
Medicare Patients
10,875
Medicare Billing
$6.5M
Payment Breakdown by Category
Food & Beverage$2,261 (87.2%)
Education$332.88 (12.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,261 | 123 | 87.2% |
| Education | $332.88 | 6 | 12.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $349.85 | 15 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $183.88 | 10 | $0 (2023) |
| Amgen Inc. | $171.62 | 6 | $0 (2023) |
| Genentech USA, Inc. | $163.09 | 10 | $0 (2023) |
| Janssen Biotech, Inc. | $154.93 | 11 | $0 (2024) |
| Merck Sharp & Dohme LLC | $153.33 | 9 | $0 (2023) |
| ABBVIE INC. | $151.27 | 7 | $0 (2024) |
| Astellas Pharma US Inc | $103.58 | 5 | $0 (2024) |
| Incyte Corporation | $99.95 | 1 | $0 (2018) |
| BeiGene USA, Inc. | $92.52 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $566.41 | 25 | Novartis Pharmaceuticals Corporation ($128.72) |
| 2023 | $374.97 | 16 | SOBI, INC ($69.99) |
| 2022 | $177.50 | 10 | EISAI INC. ($36.47) |
| 2021 | $199.53 | 13 | Bayer HealthCare Pharmaceuticals Inc. ($86.68) |
| 2020 | $256.22 | 12 | Bayer HealthCare Pharmaceuticals Inc. ($72.15) |
| 2019 | $400.36 | 24 | Novartis Pharmaceuticals Corporation ($103.15) |
| 2018 | $471.55 | 19 | Amgen Inc. ($113.82) |
| 2017 | $147.39 | 10 | E.R. Squibb & Sons, L.L.C. ($29.50) |
All Payment Transactions
129 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $30.58 | General |
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $26.36 | General |
| Category: Oncology | ||||||
| 11/25/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: Oncology | ||||||
| 11/11/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $22.71 | General |
| Category: DESMOID TUMORS | ||||||
| 10/11/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $25.63 | General |
| Category: Oncology | ||||||
| 10/10/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $14.35 | General |
| 10/07/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Oncology | ||||||
| 09/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.23 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 09/16/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $24.97 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: Oncology | ||||||
| 07/10/2024 | GENZYME CORPORATION | CABLIVI (Biological) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: Hematology | ||||||
| 06/25/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $27.07 | General |
| Category: Oncology | ||||||
| 06/17/2024 | PFIZER INC. | BOSULIF (Drug), BESPONSA, ELREXFIO | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: Oncology | ||||||
| 05/08/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Oncology | ||||||
| 04/29/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: ONCOLOGY | ||||||
| 04/19/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: Oncology | ||||||
| 03/25/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: Oncology | ||||||
| 03/15/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: Oncology | ||||||
| 03/11/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $14.61 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 47 | 2,585 | 189,651 | $7.9M | $2.4M |
| 2022 | 47 | 2,698 | 119,592 | $5.1M | $1.7M |
| 2021 | 56 | 3,036 | 229,514 | $6.2M | $1.8M |
| 2020 | 50 | 2,556 | 144,467 | $2.5M | $637,535 |
Total Patients
10,875
Total Services
683,224
Medicare Billing
$6.5M
Procedure Codes
200
All Medicare Procedures & Services
200 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 22 | 24,800 | $2.7M | $1.0M | 37.7% |
| J9119 | Injection, cemiplimab-rwlc, 1 mg | Office | 2023 | 16 | 24,780 | $1.7M | $500,167 | 28.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 38 | 13,260 | $583,440 | $235,987 | 40.4% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 39 | 5,300 | $344,500 | $84,570 | 24.5% |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2023 | 11 | 3,060 | $459,000 | $65,765 | 14.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 12 | 29,000 | $290,000 | $65,398 | 22.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 21 | 840 | $378,000 | $61,693 | 16.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 112 | 630 | $330,750 | $56,159 | 17.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 392 | 881 | $148,008 | $53,119 | 35.9% |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | Office | 2023 | 14 | 45,241 | $90,482 | $33,279 | 36.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 24 | 78 | $103,350 | $26,389 | 25.5% |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | Office | 2023 | 12 | 92 | $92,000 | $25,864 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 269 | $69,940 | $24,457 | 35.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 24 | 154 | $53,900 | $19,660 | 36.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 11 | 21,000 | $63,000 | $17,593 | 27.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 506 | 1,486 | $40,122 | $11,227 | 28.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 139 | 814 | $48,840 | $8,016 | 16.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 67 | 400 | $47,200 | $7,990 | 16.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 46 | 180 | $45,000 | $7,953 | 17.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $24,882 | $6,691 | 26.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 66 | 147 | $34,545 | $6,240 | 18.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 74 | 508 | $41,656 | $5,433 | 13.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 46 | 92 | $15,824 | $5,371 | 33.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 70 | 70 | $21,280 | $5,193 | 24.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 45 | 162 | $20,412 | $3,839 | 18.8% |
About Dr. Minesh Patel, MD
Dr. Minesh Patel, MD is a Hematology & Oncology healthcare provider based in Newnan, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2010. The National Provider Identifier (NPI) number assigned to this provider is 1699094300.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Minesh Patel, MD has received a total of $2,594 in payments from pharmaceutical and medical device companies, with $566.41 received in 2024. These payments were reported across 129 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($2,261).
As a Medicare-enrolled provider, Patel has provided services to 10,875 Medicare beneficiaries, totaling 683,224 services with total Medicare billing of $6.5M. Data is available for 4 years (2020–2023), covering 200 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Newnan, GA
- Active Since 05/19/2010
- Last Updated 05/11/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1699094300
Products in Payments
- IMBRUVICA (Drug) $166.75
- Nubeqa (Drug) $155.08
- KEYTRUDA (Biological) $138.01
- MEKINIST (Drug) $125.03
- VENCLEXTA (Drug) $103.73
- LIBTAYO (Biological) $91.41
- Doptelet (Drug) $86.05
- BRUKINSA (Drug) $76.91
- Perjeta (Biological) $71.75
- SCEMBLIX (Drug) $69.04
- Lenvima (Drug) $66.49
- Orserdu (Drug) $64.51
- KISQALI (Drug) $59.68
- GAZYVA (Biological) $50.91
- ADCETRIS (Biological) $49.16
- PROMACTA (Drug) $46.84
- DARZALEX (Biological) $44.57
- LUMAKRAS (Drug) $43.29
- XTANDI (Drug) $38.69
- Enhertu (Drug) $33.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Newnan
Dr. Vasileios Assikis, M.d, M.D
Hematology & Oncology — Payments: $64,440
Hematology & Oncology $64,440
Dr. Bamidele Adesunloye, Md, MD
Hematology & Oncology — Payments: $37,146
Hematology & Oncology $37,146
Nitika Sharma, M.d, M.D
Hematology & Oncology — Payments: $4,497
Hematology & Oncology $4,497